Table 4. Immunohistochemistry staining of lung cancer tissues compared with normal lung tissues published in the Human Protein Atlas website* for the differentially expressed genes identified in this study associated with tumor progression and/or chemotherapy signatures.
| Increased# | Decreased# | Same# | Not expressed# |
| SLC22A16, TOP2A,EP300, NRG1, DUPD1,DAPP1, PTPRN2, PTPRT, PTPRZ1, ITGB8, S100A15, TIMP4, CCR2, BCL2L1, STAT1,CXCR4, PRKCZ, S100A8, MAPK14, BAD,SHC1, MAPRE1, TTK, STXBP1, TRAM1 | SLC22A4, GNMT,ICMT, FIGF, BMP1,FGF3, CECR1, INHBE, PLSCR4, PLA2G4F, PLA2G10, SGMS2, CD1D, DDX58, TLR4,LXN, PF4, KIT, DOK2, PIK3CD, TLR5,BCL3, RASA1, ELK1, APBA1,STXBP2 | HAT1, BDNF,PTPRN, PIK3C3, SERINC1, SPTLC1, C1QC, IL1RAP, DEFB118, CTNNA2,TIMP1, TIMP2, FES, FKBP5, IL4R, PLCG1, IFNB1, CD86, ATP6AP2, PTK2, CREBBP, PTPN6, KIF20A, CENPE, PRC1, MAP7, SMC1A, TUBB4, MAP3K11, UNC84B, RAB2A, COPB1, DOP2, TOP1MT, CARM1, MYST2, PTPRA, PTPRE | CEL, ACPP, INPP5D |
#
Increased, decreased, the same, or not expressed in protein levels of lung cancer tissues, compared with that of normal lung tissues in the Human Protein Atlas.